What Whiterabbit.ai does

Whiterabbit.ai is a venture-backed, US-based artificial intelligence company founded in 2017 and headquartered in Redwood City, California. The company develops FDA-cleared deep learning software for breast cancer screening, with a stated mission to reduce late-stage breast cancer through earlier detection. Its commercially available product portfolio comprises two products: WRDensity, an AI-driven software that classifies breast density from mammograms and is reported to deliver 43% more longitudinal consistency than radiologists; and WRRisk, a clinical decision support tool that estimates 10-year and lifetime breast cancer risk by integrating structured patient data with WRDensity output.

The underlying technology is built on a proprietary dataset spanning 11M+ datapoints across 2M+ patients, with the WRDensity model itself trained on over 600,000 mammogram images sourced from the Mallinckrodt Institute of Radiology. The company operates with 50+ AI scientists, engineers, and healthcare professionals and is constrained to US users per its privacy policy. Distribution combines direct enterprise sales to radiology practices, hospital systems, and breast imaging centers with channel placement on the American College of Radiology's AI-LAB / ACR Connect platform, where WRDensity was the first FDA-cleared AI-driven breast density product to be listed (November 2023).

The business model is enterprise subscription licensing of AI software to healthcare providers on annual contracts with quote-based, non-public pricing. Revenue comes primarily from healthcare-provider customers, with a stated secondary segment of healthcare payors for risk-based screening programs. The company has entered comprehensive commercial and research partnerships with RadNet, Onsite Women's Health, Stanford Medicine, Washington University, Mallinckrodt Institute of Radiology, and the American College of Radiology, and has secured at least two funding rounds (2019, 2020) from investors including Celesta Capital, with no disclosed revenue or funding totals.

Name

Whiterabbit.ai

Legal name

Whiterabbit.ai, Inc.

Website

https://whiterabbit.ai

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Whiterabbit.ai develops FDA-cleared deep learning AI software for breast cancer screening, offering WRDensity for density assessment and WRRisk for risk evaluation, and licenses these products on an enterprise subscription basis to US radiology practices, hospital systems, and breast imaging centers.

Ownership category

akta.pro rank

Product category

AI Radiology / Breast Imaging Software

NAICS

Software Publishers (513210)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Mammography & Breast Imaging Systems (HLAHABAF)

Keywords

• AI medical imaging
• Breast cancer screening
• Mammography AI software
• Clinical decision support
• Radiology AI

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI Software Licensing: FDA-cleared AI software products (WRDensity and WRRisk) licensed to healthcare providers including radiology practices, hospital systems, and breast imaging centers. Products provide clinical decision support for breast density assessment and cancer risk evaluation.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Whiterabbit.ai develops and licenses FDA-cleared artificial intelligence software that assists radiologists in breast cancer screening. Its two commercial products, WRDensity (AI-driven breast density classification) and WRRisk (clinical decision support for breast cancer risk assessment), are sold on a subscription basis to radiology practices, hospital systems, and breast imaging centers for use in mammography workflows.

Product overview

Whiterabbit.ai offers a unified AI-powered product portfolio for breast cancer screening, comprising two commercially available FDA-cleared products: WRDensity (AI-driven breast density assessment) and WRRisk (clinical decision support for breast cancer risk assessment). These products are designed to work together, with WRRisk integrating WRDensity data to provide comprehensive risk-based screening recommendations, driving clinical precision and operational efficiency across the care continuum.

Differentiator

Problem solved

Functional benefit

Brands

• WRDensity: AI-driven breast density software that assists radiologists in interpreting breast density to create uniformity of density assessment at the practice level. FDA-cleared artificial intelligence-driven software that helps radiologists better assess breast density.
• WRRisk

Products and services

• WRDensity FDA-cleared, AI-driven deep learning software that assists radiologists in interpreting mammographic breast density and produces a uniform, practice-level density classification. It is trained on more than 600K mammogram images from Mallinckrodt Institute of Radiology and has been shown to deliver 43% more consistent longitudinal assessments than radiologists. Targeted at radiology practices, hospital systems, and breast imaging centers for use in mammography screening workflows.
• WRRisk Clinical decision support software for breast cancer risk assessment that simplifies breast risk program maintenance by replacing paper forms and automating steps from intake to letter generation. It computes 10-year and lifetime breast cancer risk scores, integrates density data from WRDensity, and supports personalized screening recommendations. Targeted at breast imaging centers, radiology practices, and payor/provider programs running risk-based screening.

Quantifiable outcome

• 43% more consistent than radiologists when assessing patient exams across multiple years
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• American College of Radiology (ACR)coreTechnology or Integration · 7 November 2023Collaboration with ACR Data Science Institute (DSI) to make WRDensity available on ACR's AI-LAB platform. WRDensity is the first FDA-cleared, commercial algorithm on the ACR Connect platform alongside 12 investigational models from other parties. Enables democratized access to AI for radiologists.
• Onsite Women's HealthmajorStrategic or Co-development Partner · 27 October 2022Research collaboration with Onsite Women's Health, a leading national provider of breast health services. Joint longitudinal study of breast density using AI presented at RSNA 2022. Onsite operates in 25 states providing 3D Tomosynthesis mammography screening.
• RadNetcoreStrategic or Co-development Partner · 19 August 2022Comprehensive partnership with RadNet, a leading national provider of breast health services, to address mammography compliance and improved diagnostics for breast cancer. RadNet operates multiple radiology sites using Whiterabbit's AI products.
• Mallinckrodt Institute of RadiologycoreTechnology or IntegrationData partnership providing training images for AI model development. WRDensity is trained on over 600K images from Mallinckrodt Institute of Radiology, enabling the deep learning model to deliver highly accurate breast density classification.
• Stanford UniversitycoreStrategic or Co-development PartnerClinical research partnership with Stanford Medicine to evaluate the impact of AI on radiologists' performance. Partnership includes retrospective study with Stanford University School of Medicine evaluating the long-standing assumption that AI does not influence radiologists' performance.
• Washington University in St. LouiscoreStrategic or Co-development PartnerCollaborative research with Washington University School of Medicine's Breast Image Computing Lab, led by Aimilia Gastounioti, Assistant Professor of Radiology. Joint longitudinal study on AI in breast density assessment presented at RSNA 2022.
• Guardant HealthminorOthersListed as industry partner and collaborator. Guardant Health is a precision medicine company focused on blood-based testing for cancer.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Volpara Health: Volpara Health is a direct peer: it sells AI-driven breast density assessment and breast cancer risk analytics (Volpara Density, RiskScore, Live) to the same radiology and breast imaging centers as Whiterabbit, using similar deep-learning approaches on mammography images.
• Lunit: Lunit is a direct peer offering Lunit INSIGHT MMG, an AI mammography analysis product competing head-to-head with Whiterabbit's WRDensity for radiology AI decision support on breast imaging exams, with a broadly overlapping customer profile of hospital systems and imaging centers.
• DeepHealth (formerly iCAD): DeepHealth acquired iCAD's AI breast health business and sells mammography AI for density, cancer detection, and risk, in direct competition with Whiterabbit across the same radiology provider customer base.
• ScreenPoint Medical: ScreenPoint Medical develops Transpara, an AI-based breast imaging decision-support product for mammography, offering comparable workflow and CAD-style triage functionality to Whiterabbit's WRDensity across hospital radiology sites.
• Densitas: Densitas provides AI-driven breast density and mammography quality analytics directly to breast imaging centers and is comparable as a focused breast-density AI SaaS competitor to Whiterabbit's WRDensity.

Emerging players

• Therapixel: Therapixel offers MammoScreen, an AI mammography analysis tool competing in the same breast imaging AI category as Whiterabbit, with a narrower initial geographic and OEM footprint but overlapping product functionality.

Broad incumbents

• Hologic: Hologic is the dominant U.S. mammography equipment vendor and increasingly embeds AI for breast density and cancer detection directly into its 3Dimensions and Genius AI ecosystem, representing a broad incumbent that could compete or partner with Whiterabbit across the same radiology customers.
• GE HealthCare: GE HealthCare provides mammography hardware, PACS, and an expanding portfolio of Edison AI radiology applications that compete with Whiterabbit at the broad health-system AI decision-support layer that includes breast imaging.
• Siemens Healthineers: Siemens Healthineers sells mammography systems and AI-Rad Companion radiology AI software that address breast density and oncology workflows overlapping with Whiterabbit's clinical use cases across enterprise imaging customers.
• Philips: Philips operates a large radiology informatics portfolio (IntelliSpace) and develops AI for mammography and oncology, serving the same health-system radiology buyers that Whiterabbit targets with its AI breast imaging SaaS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/whiterabbitai

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Whiterabbit.ai